In this segment from Market Checkup, Motley Fool's health-care focused investing show, analysts David Williamson and Max Macaluso look at Merck's recent quarterly results. 

The Big Pharma posted declining revenue and net income, missing analyst estimates in the process. However, investors need to dig behind the top-line numbers to get a clear picture of Merck's potential. Guidance for 2014 was not a bad as feared, although it will be a transition year for the company. That doesn't mean the stock is stuck on timeout. Merck's pipeline has a lot of potential, and the company is striking collaboration agreements left and right.

In this video, David and Max dig through the quarterly results and discuss Merck's focus on immuno-oncology, its new partnership deals, and other interesting upcoming pipeline catalysts.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.